Takeda Pharmaceutical Company Limited
TAK
$13.88
$0.010.07%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -74.81% | 1.34% | 3,105.63% | -102.84% | 315.43% |
| Total Depreciation and Amortization | -5.32% | 4.99% | 18.75% | -18.06% | 0.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 293.17% | -161.22% | 95.42% | 79.19% | 486.15% |
| Change in Net Operating Assets | 121.95% | 121.51% | -404.71% | 135.56% | -334.71% |
| Cash from Operations | 33.12% | 73.01% | -41.78% | 89.15% | -27.94% |
| Capital Expenditure | 11.18% | 9.68% | -22.83% | 5.94% | -21.75% |
| Sale of Property, Plant, and Equipment | -73.09% | 238.13% | 327.41% | -99.25% | -96.86% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -77.21% | 92.16% | -85.71% | -- | 100.00% |
| Other Investing Activities | -124.98% | 68.11% | -166.34% | -27.70% | 10.31% |
| Cash from Investing | -49.90% | 49.72% | -142.71% | 18.78% | -21.60% |
| Total Debt Issued | -91.61% | -6.07% | 17,021.27% | -101.76% | -- |
| Total Debt Repaid | 6.50% | -600.25% | -591.96% | 88.32% | 38.56% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1,441.03% | 93.02% | -1,341.26% | 93.44% | -1,392.64% |
| Other Financing Activities | -26.65% | -216.96% | 176.85% | -5.51% | -229.52% |
| Cash from Financing | -480.96% | -136.48% | 617.51% | 40.78% | 31.98% |
| Foreign Exchange rate Adjustments | 153.37% | -354.46% | 55.30% | 437.09% | -176.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -758.53% | -83.69% | 95.15% | 667.41% | -1,838.09% |